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Abstract
Background: Evidence suggests that elevated systolic blood pressure (SBP) and pulse pressure (PP) in midlife is associated
with increased risk for cognitive impairment later in life. There is mixed evidence regarding the effects of late life elevated
SBP or PP on cognitive function, and limited information on the role of female gender.
Methods/Principal Findings: Effects of SBPand PPon cognitive abilities at baseline and over a 9-year period were evaluated
in 337 non-demented community-dwelling female participants over age 70 in the Women’s Health and Aging Study II using
logistic and Cox proportional hazards regression analyses. Participants aged 76–80 years with SBP$160 mmHg or
PP$84 mmHg showed increased incidence of impairment on Trail Making Test-Part B (TMT, Part B), a measure of executive
function, over time when compared to the control group that included participants with normal and pre-hypertensive SBP
(,120 and 120–139 mmHg) or participants with low PP (,68 mmHg) (HR=5.05 [95%CI=1.42, 18.04], [HR=5.12
[95%CI=1.11; 23.62], respectively). Participants aged 70–75 years with PP$71 mmHg had at least a two-fold higher
incidence of impairment on HVLT-I, a measure of verbal learning, over time when compared to participants with low PP
(,68 mmHg) (HR=2.44 [95%CI=1.11, 5.39]).
Conclusions/Significance: Our data suggest that elevated SBP or PP in older non-demented women increases risk for late-
life cognitive impairment and that PP could be used when assessing the risk for impairment in cognitive abilities. These
results warrant further, larger studies to evaluate possible effects of elevated blood pressure in normal cognitive aging.
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Introduction
Hypertension (HTN), an elevation of systolic or diastolic or both
systolic and diastolic blood pressures, is an important public health
issue because of its high prevalence, approximately 26% in the
general population [1], and because of associated high morbidity
and mortality [2]. There is also evidence that age-related blood
pressure changes occur and that these changes are gender-specific,
namely systolic hypertension is more prevalent in elderly women
than men [3]. These age-related blood pressure changes may
account, in part, for the higher cardiovascular mortality reported
among elderly females compared with elderly males [4–6], and
should be considered an important target for preventive strategies
in elderly females.
HTN has been extensively studied as a major risk factor for
cognitive decline in older; community dwelling populations (see
review [7]). While there is strong evidence that HTN in midlife is
associated with increased risk for cognitive impairment later in life
[8–13], there is mixed evidence regarding the effects of HTN in
late life on cognitive function. One study reported no association
[14], while other studies reported negative associations [15–18]
between elevated baseline systolic blood pressure (SBP) and global
cognitive function. Additionally, it is not clear whether specific
cognitive abilities are more susceptible to the effects of elevated
blood pressure in late life as one study showed a negative
association between elevated SBP and learning and memory [19],
another a negative association with attention, [20] and a third
showed a negative association with naming and non-verbal
memory [21]. There is currently no study available with a special
focus on the role of SBP in late life and its effect on cognitive
abilities in older women.
Pulse pressure (PP) is an independent predictor of all-cause and
cardiovascular mortality [22]. High PP has been associated with
Alzheimer’s disease (AD) [23], poorer global cognitive function
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memory in individuals without dementia [25], when compared to
participants with lower PP. However, there is currently no
information available with a focus on the role of PP in late life
and its effect on cognitive abilities in older women.
In the present study, we examined whether elevated SBP or PP
in older women was associated with changes in cognitive abilities
at baseline and over a 9-year period in a population of non-
demented community-dwelling female participants, aged 70 to 80
years at baseline, in the Women’s Health and Aging Study
(WHAS) II.
Methods
Ethics Statement
This study was approved by the Johns Hopkins Institutional
Review Board, and each participant gave informed, written
consent before completing a standardized interview at each exam.
Data Source and Study Population
This study involved secondary data analysis using the WHAS II,
a prospective study of physical functioning among the least
disabled two thirds of 70- to 80-year-old, community dwelling
women in eastern Baltimore, MD. Sampling and recruitment of
this cohort is described in detail elsewhere [26] and complements
WHAS I, a study of the one-third most disabled, community-
dwelling older women. Trained interviewers determined eligibility
at sampling according to whether individuals were (a) aged 70–79
years; (b) had sufficient hearing and proficiency in English to be
interviewed; (c) could be contacted by telephone; (d) had a Mini-
Mental State Exam (MMSE) [27] score .24; and (e) reported
difficulty in no more than one of four functional domains: mobility
and exercise tolerance, upper extremity strength, higher function-
ing (e.g., shopping), and basic self-care. Of 880 eligible individuals,
436 agreed to participate in the baseline examination. Those
agreeing to participate were more highly educated and had more
diseases than those who refused, but did not differ in other
characteristics. Five follow-up exams were conducted at approx-
imately 1.5-year intervals, with the exception of a 3-year interval
between Exams 3 and 4, yielding a maximum of 9 years of follow-
up. Each follow-up visit was conducted in the clinic or home, as
needed and included standardized physical, cognitive and
functional evaluations, and collection of demographic, psychoso-
cial, medical and medication information. Over 9 years, 90
participants died and 103 participants were lost to follow-up.
Individuals who were missing blood pressure information at
baseline were excluded (N=2). Individuals who had scores under
the impairment threshold (described below) were later excluded
for longitudinal analyses (N=98). The 336 remaining individuals
represent 77.3% of the 436 participating individuals, and were
included in both the cross-sectional and longitudinal analyses. The
100 individuals excluded from this study were comparable to those
included in the study on age, systolic or diastolic blood pressure,
and history of hypertension, but had lower MMSE scores
(p,0.001), lower education (p,0.001), and were more likely to
be black or other race (p,0.001).
Measures of Cognitive Function
Standardized cognitive testing by a trained technician was
designed to comprehensively assess cognitive abilities in healthy
older adults, and to be maximally sensitive to changes occurring
with normal aging and to pathological changes occurring with
dementia. Global cognitive status was assessed by the Mini-Mental
State Exam (MMSE). The MMSE assesses five areas of cognitive
function including orientation, attention, calculus, recall and
language. The maximum score is 30 and a score of 24 or lower is
suggestive of cognitive impairment. The Trail Making Test (TMT)
[28], which is a pencil-and-paper test, was used to evaluate
psychomotor speed via Part A and B, and executive function via
Part B. Part A requires one to connect, as quickly as possible, a
randomly distributed array of numbers sequentially from 1 to 25.
Part B requires one to connect randomly distributed numbers and
letters in an ascending alpha-numeric sequence. Participants were
allotted amaximumtimeof240 seconds onPartA and360 seconds
on Part B. Verbal immediate and delayed recall memory of 12
common objects were assessed using the Hopkins Verbal Learning
Test-Revised (HVLT-R) [29]. Participants heard and recalled
words during three successive learning trials (maximum=36) and
once after a 20-minute interval (maximum=12).
Impairment on each of the cognitive assessments was defined as
follows: Trail Making Part A (TMT-A) scores $81 seconds; Trail
Making Part B (TMT-B) scores $225 seconds; Hopkins Verbal
Learning Test immediate recall (HVLT-I) scores #16; Hopkins
Verbal Learning Test delayed recall (HVLT-D) scores #4;
MMSE scores #23 [30,31]. These cut-points corresponded to
approximately 1.5 to 1.8 standard deviations below internal norms
at baseline on most tests.
Measures of Blood Pressure
At each study visit, blood pressure (BP) was measured by a
trained nursing staff according to protocols. The participant’s BP
was measured while the participant was resting and sitting in an
upright position with legs uncrossed and feet flat on the floor for
approximately five minutes. Three blood pressure readings, with
30-second intervals between each measurement, were obtained on
the right arm using a mercury sphygmomanometer with an
appropriate-sized occluding cuff and were averaged for data
analysis.
Systolic hypertension status was stratified according to SBP
readings as control group (SBP#139 mmHg), HTN I group
(SBP=140–159 mmHg) and HTN II group (SBP$160 mmHg)
PP, was defined as the difference between SBP and DBP, and
participants were assigned to the lower (PP=48–68 mmHg),
middle (PP=71–77 mmHg) and upper (PP=84–108 mmHg)
tertile group according to their PP, where the lower tertile group
served as the control group.
Statistical Analyses
STATA 10.2 was used for all analyses (StataCorp, College
Station, TX). We compared baseline demographic and health
characteristics by HTN stage and PP tertile using chi-square tests
for categorical variables and ANOVA with pair wise comparisons
for continuous variables. In order to assess the baseline prevalence
of impairment in cognitive abilities first cross-sectional analysis,
using logistic regression models, were conducted. In order to assess
the long-term effect of SBP and PP on the risk of developing
impairment in each cognitive ability over the 9-year follow-up
period, longitudinal, multivariate discrete-time Cox proportional
hazard models [32] were conducted. The discrete-time Cox
models have advantages over traditional, continuous proportional-
Cox models in that the event, such as last visit or death, can occur
over a discrete time; use of this model is especially appealing in
analyzing longitudinal data with regularly scheduled visits. The
model compares each case of newly diagnosed impairment with all
other subjects in the study who were free of impairment at that
visit when the impairment was diagnosed. Subjects contributed
information up to the visit when the diagnosis of impairment
occurred, or up to their last study visit.
Systolic BP on Cognitive Function
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confounding effects of age [33], race (white vs. non-white) [34]
and education (,12, =12, .12 years of education) [35]. Then,
in Model 2, in addition to age, race, and education they were
adjusted for income (,$10,000/yr, $10,000–24,999/yr, $25,000–
49,999, .$50,000/yr), smoking status (never vs. ever), comor-
bidities such as history of HTN, stroke, myocardial infarction
(MI) or angina, congestive heart failure (CHF), peripheral artery
disease (PAD), diabetes mellitus (DM); depression (measured by
Geriatric Depression Scale [36]), Body Mass Index (BMI, Body
Table 1. Baseline Sociodemographic Characteristics of Participants by Hypertension Status and Pulse Pressure, WHAS II (N=336).
Characteristics PP PP PP Statistics
Control Group HTN I HTN II Statistics Lower Tertile Middle Tertile
Upper
Tertile
(N=103) (N=124) (N=109) p (N=117) (N=107) (N=112) p
N( % ) N( % )
Age (Mean, SD) 73.5 (2.9) 73.7 (2.8) 74.1 (2.7) 0.2 73.4 (2.7) 73.9 (2.9) 74.02 (2.7) 0.2
Race:
White 87 (84.5) 101 (81.5) 97 (89.0) 0.3 90 (76.9) 95 (88.8) 99 (88.4) 0.02
Education:
,12 years 9 (8.7) 11 (8.9) 7 (6.4) 0.5 12 (10.3) 12 (11.2) 3 (2.7) 0.01
=12 years 43 (41.7) 61 (49.2) 57 (52.3) 48 (41.0) 45 (42.1) 68 (60.7)
.12 years 51 (49.5) 52 (41.9) 45 (41.3) 57 (48.7) 50 (46.7) 41 (36.6)
Income ($/year):
,10,000 20 (24.4) 25 (24.5) 21 (23.1) 0.5 24 (24.5) 24 (27.9) 18 (20.0) 0.6
10,000–24,999 27 (32.9) 32 (31.4) 38 (41.8) 33 (33.7) 26 (30.2) 38 (42.2)
25,000–49,999 19 (23.2) 23 (22.6) 22 (24.2) 26 (26.5) 20 (23.3) 18 (20.0)
.50,000 16 (19.5) 22 (21.6) 10 (11.0) 15 (15.3) 16 (18.6) 16 (17.8)
Marital status:
Married 64 (62.1) 70 (56.5) 70 (64.2) 0.4 77 (65.8) 60 (56.1) 68 (60.7) 0.3
Not Married 39 (37.9) 54 (43.6) 39 (35.8) 40 (34.2) 47 (43.9) 44 (39.3)
Smoking:
Never 57 (55.3) 67 (54.0) 57 (52.8) 0.91 65 (55.6) 59 (55.1) 58 (52.3) 0.9
Ever 46 (44.7) 57 (46.0) 51 (47.2) 52 (44.4) 48 (44.9) 53 (47.8)
Hx HTN 29 (27.9) 68 (54.8) 75 (68.8) ,0.001 51 (43.6) 52 (48.6) 69 (61.6) 0.02
Hx Stroke 4 (3.9) 4 (3.2) 4 (3.7) 0.7 5 (4.3) 4 (3.7) 3 (2.7) 0.5
Hx MI 6 (5.8.2) 11 (8.9) 11(10.1) 0.5 5 (4.3) 7 (6.5) 16 (14.3) 0.02
Hx Angina 19 (8.3) 18 (14.5) 14 (12.8) 0.5 16 (13.7) 19 (17.6) 16 (14.3) 0.7
Hx CHF 6 (5.8) 8 (6.5) 9 (8.3) 0.8 10 (8.6) 2 (1.9) 11 (9.8) 0.04
Hx PAD 10 (9.6) 9 (7.3) 12 (11.0) 0.6 12 (10.3) 6 (5.6) 13 (11.6) 0.3
Hx DM 8 (7.7) 12 (9.7) 6 (5.5) 0.5 11 (9.4) 7 (6.5) 8 (7.1) 0.7
Ever taking HTN medications
54 (51.9) 101 (81.5) 92 (84.4) ,0.001 77 (65.8) 79 (73.8) 90 (80.4) 0.04
Mean (SD) Mean (SD)
SBP (mmHg) 129.1 (9.1) 148.9 (5.0) 177.6 (12.0) ,0.001 138.1 (18.4) 150.6 (17.1) 167.9 (17.1) ,0.001
DBP (mmHg) 67.4 (10.1) 73.4 (11.8) 88.2 (17.0) ,0.001 80.0 (15.9) 76.6 (16.8) 72.1 (13.5) ,0.001
PP (mmHg) 61.7 (12.6) 75.5 (12.7) 89.5 (17.7) ,0.001 58.1 (10.0) 73.9 (3.4) 95.8 (12.0) ,0.001
BMI 25.9 (5.7) 27.3 (5.0) 26.5 (4.6) 0.1 26.7 (5.4) 26.2 (4.5) 27.0 (5.4) 0.5
GDS 3.7 (3.6) 3.9 (4.1) 3.5 (2.9) 0.7 3.4 (3.3) 4.2 (4.0) 3.7 (3.5) 0.3
Mean years to follow up
6.4 (8.7) 7.0 (6.0) 6.6 (6.2) 0.8 6.4 (8.2) 7.4 (4.9) 6.3 (7.3) 0.4
Control group (SBP#139 mmHg); HTN I=Hypertension I (SBP 140–159 mmHg); HTN II=Hypertension II (SBP$160); PP lower tertile=Pulse pressure 48–68 mmHg, PP
middle tertile=Pulse pressure 71–77 mmHg, and PP upper tertile=Pulse pressure 84–108 mmHg.
Statistics=Chi-square test was used for categorical and ANOVA with pairwise comparisons for continuous variables.
Hx HTN=history of high blood pressure, Hx stroke=history of stroke, Hx MI=history of myocardial infarction, Hx Angina=history of angina, Hx CHF=history of
congestive heart failure, Hx PAD=history of peripheral artery disease, Hx DM=history of diabetes mellitus; BMI=Body Mass Index, GDS=Geriatric Depression Scale.
doi:10.1371/journal.pone.0027976.t001
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2), serum glucose level (mg/dl), total cholesterol
level (mg/dl), and history of ever taking antihypertensive
medications. The a priori p-value was set at p,0.05.
First, we evaluated the effect of SBP and PP on cognitive
abilities in all participants, then, in separate analyses, we stratified
subjects according to their age, 70–75 years old or 76–80 years
old, to evaluate the possible role of age.
Table 2. Means (SD) of Performances of Global and Domain Specific Cognitive Function for Exam 1–6 (9-year interval).
Exam 1 Exam 2 Exam 3 Exam 4 Exam 5 Exam 6
Mean (SD)
MMSE 28.6 (1.4) 28.4 (1.8) 27.9 (2.1) 28.1 (2.5) 27.9 (2.4) 27.4 (3.0)
TMT, Part A 40.3 (12.2) 45.0 (22.0) 47.1 (24.9) 52.1 (29.1) 53.1 (33.5) 55.5 (30.6)
TMT, Part B 104.1 (35.7) 119.1 (61.1) 140.0 (80.7) 161.1 (95.2) 174.7 (104.3) 179.8 (103.2)
HVLT-I 24.2 (4.1) 23.5 (4.7) 24.3 (5.2) 22.4 (5.6) 21.8 (5.5) 22.7 (6.4)
HVLT- D 9.1 (1.9) 8.6 (2.4) 8.7 (2.5) 7.8 (2.9) 7.7 (3.1) 7.5 (3.4)
MMSE=Mini Mental State Exam; TMT, Part A=Trail Making Test, Part A; TMT, Part B=Trail Making Test, Part B; HVLT=Hopkins Verbal Learning Test (HVLT-I=immediate
recall; HVLT-D=delayed recall).
doi:10.1371/journal.pone.0027976.t002
Table 3. Cross-Sectional Analysis of Hypertension Stages and Pulse Pressure Tertiles on Cognitive Function at Baseline.
HTN I HTN II PP Middle Tertile PP Upper Tertile
HR (95%CI) HR (95%CI) HR(95%CI) HR (95%CI)
HVLT-D
Unadjusted 0.75(0.32,1.76) 0.92(0.40,2.12) 0.74(0.31,1.76) 0.94(0.42,2.10)
Model 1 0.75(0.31,1.80) 1.08(0.45,2.58) 0.80(0.32,1.96) 1.19(0.51,2.77)
Model 2 0.75(0.28,1.99) 1.37(0.51,3.70) 0.71(0.27,1.87) 1.44(0.56,3.67)
HVLT-I
Unadjusted 0.96(0.44,2.10) 1.24(0.58,2.65) 0.65(0.30,1.42) 0.85(0.41,1.75)
Model 1 0.96(0.42,2.16) 1.41(0.63,3.15) 0.65(0.29,1.48) 1.00(0.47,2.14)
Model 2 0.77(0.30,1.97) 1.59(0.62,4.07) 0.52(0.21,1.28) 0.98(0.42,2.31)
TMT, Part A
Unadjusted 0.45(0.18,1.11) 0.43(0.17,1.11) 0.37(0.13,1.04) 0.56(0.23,1.37)
Model 1 0.35(0.12,0.98)* 0.59(0.21,1.67) 0.44(0.14,1.38) 0.92(0.33,2.53)
Model 2 0.29(0.09,0.96)* 0.49(0.13,1.79) 0.36(0.09,1.38) 0.95(0.30,2.98)
TMT, Part B
Unadjusted 1.42(0.60,3.39) 1.65(0.69,3.95) 0.74(0.31,1.80) 1.28(0.59,2.79)
Model 1 1.07(0.43,2.72) 1.56(0.62,3.90) 0.65(0.25,1.67) 1.36(0.60,3.12)
Model 2 1.26(0.42,3.73) 2.12(0.71,6.35) 0.75(0.26,2.16) 2.09(0.82,5.35)
MMSE
Unadjusted 0.20(0.02,1.85) 0.69(0.15,3.12) 0.23(0.03,1.98) 0.43(0.08,2.26)
Model 1 0.15(0.01,1.45) 0.80(0.16,4.06) 0.24(0.03,2.16) 0.45(0.08,2.48)
Model 2 0.08(0.01,1.05) 0.24(0.03,2.09) 0.18(0.01,2.32) 0.25(0.03,2.29)
Reference group for HTN: control group (SBP#139 mmHg); for PP: pulse pressure lower tertile (48–68 mmHg).
HTN I=Hypertension I (SBP 140–159 mmHg); HTN II=Hypertension II (SBP$160); PP middle tertile=Pulse pressure 71–77 mmHg, and PP upper tertile=Pulse pressure
84–108 mmHg.
Model 1: age, race, education.
Model 2: age, race, education, history of high blood pressure, stroke, myocardial infarction, congestive heart failure, peripheral artery disease, diabetes mellitus, angina;
history of smoking, BMI, ever on hypertensive medication, glucose, cholesterol, and depression score.
Note: All Trails B models adjust for Trails A performance.
MMSE=Mini Mental State Exam; TMT, Part A=Trail Making Test, Part A; TMT, Part B=Trail Making Test, Part B; HVLT=Hopkins Verbal Learning Test (HVLT-I=immediate
recall; HVLT-D=delayed recall);
*p-value,0.05.
** p-value,0.01.
doi:10.1371/journal.pone.0027976.t003
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Participants
Theaverage ageofthe336 participantsatbaselinewas74.1years
(ranging from 70–80 years), 41% had a college education and 81%
were white (Table 1). 51% reported history of HTN and 52%
reported antihypertensive medication use (Table 1). The prevalence
of stroke, MI, angina, CHF, PAD, and DM, was 3.6%, 8.9%,
14.9%, 7.6%, 9.6% and 9.4%, respectively. The baseline means for
MMSE, TMT Part A and Part B times (sec), and HVLT-I and -D
scores were indicative of a high functioning sample (Table 2).
The participants in the HTN II group had higher prevalence of an
HTN history and reported antihypertensive medication use, and
higher SBP, DBP and PP, compared to the control group. The
participants in the upper tertile PP group were more often white, had
lower education levels, had a higher prevalence of HTN history, MI
history, CHF history, reported antihypertensive medication use, and
higher SBP, DBP and PP compared to the control group (Table 1).
SBP and Cognitive Function
In the cross sectional analyses, participants with HTN I had
lower odds of impairment on the TMT, Part A (HR=0.29
[95%CI=0.09, 0.96]) compared to the control group. There were
no differences in HTN I and II groups, and the control group in
odds of impairment on the MMSE, TMT Part B, HVLT-I,
HVLT-D after full adjustment in Model 2 (Table 3).
In the longitudinal analyses risk of cognitive impairment on any
test did not differ by SBP levels (Table 4). However, when
participants were stratified according to their age, participants
aged between 76 and 80 years in the HTN II group had a five-fold
greater increased risk of impairment on TMT-B compared to the
control group (HR=5.05 [95%CI=1.42, 18.04]). There were no
associations between SBP levels and risk of cognitive impairment
among those aged 70–75 (Table 5).
PP and Cognitive Function
In cross sectional analyses odds of impairment on any cognitive
test did not differ by PP tertile (Table 3).
In the longitudinal analyses, participants in the upper versus
lower tertile, had a greater risk of impairment in executive
function assessed by TMT, Part B (HR=2.14 [95%CI=1.29,
3.57]) compared to the lower tertile. Notably, this association was
largely driven by the women aged 76–80 years old in the highest
PP tertile who had a five-fold greater risk of TMT, Part B
Table 4. Longitudinal Analysis of Hypertension Stages and Pulse Pressure Tertiles on Cognitive Decline.
HTN I HTN II PP Middle Tertile PP Upper Tertile
HR (95% CI) HR (95% CI) HR (95% CI) HR (95% CI)
HVLT-D
Unadjusted 1.18 (0.70–2.00) 1.02 (0.58–1.78) 0.97 (0.57–1.65) 1.06 (0.63–1.80)
Model 1 1.06 (0.62–1.81) 0.96 (0.54–1.68) 0.97 (0.56–1.66) 1.13 (0.65–1.96)
Model 2 1.23 (0.67–2.27) 1.16 (0.60–2.23) 0.88 (0.50–1.55) 1.24 (0.69–2.22)
HVLT-I
Unadjusted 1.12 (0.67–1.87) 1.05 (0.61–1.80) 1.56 (0.92–2.62) 1.27 (0.74–2.18)
Model 1 1.08 (0.64–1.81) 1.03 (0.59–1.78) 1.74 (1.01–2.99)* 1.45 (0.82–2.58)
Model 2 1.35 (0.75–2.41) 1.37 (0.73–2.55) 1.53 (0.88–2.68) 1.58 (0.87–2.90)
TMT, Part A
Unadjusted 1.49 (0.81–2.75) 1.34 (0.70–2.56) 0.87 (0.47–1.61) 1.11 (0.62–1.98)
Model 1 1.34 (0.71–2.50) 1.43 (0.74–2.75) 1.04 (0.55–1.95) 1.59 (0.85–2.97)
Model 2 1.44 (0.69–2.99) 1.60 (0.75–3.45) 0.93 (0.46–1.89) 1.49 (0.75–2.93)
TMT, Part B
Unadjusted 1.12 (0.67–1.88) 1.20 (0.72–2.01) 0.88 (0.55–1.43) 1.46 (0.95–2.26)
Model 1 1.03 (0.61–1.73) 1.15 (0.68–1.93) 1.02 (0.62–1.69) 1.88 (1.16–3.02)
Model 2 0.90 (0.49–1.65) 1.27 (0.70–2.32) 0.98 (0.58–1.64) 2.14 (1.29–3.57)**
MMSE
Unadjusted 0.90 (0.42–1.91) 1.82 (0.92–3.60) 0.96 (0.48–1.95) 1.28 (0.66–2.48)
Model 1 0.80 (0.37–1.71) 1.84 (0.92–3.67) 1.15 (0.56–2.36) 1.54 (0.75–3.13)
Model 2 0.83 (0.36–1.97) 1.93 (0.86–4.36) 1.11 (0.53–2.35) 1.27 (0.59–2.74)
Reference group for HTN: control group (SBP#139 mmHg); for PP: pulse pressure lower tertile (48–68 mmHg).
HTN I=Hypertension I (SBP 140–159 mmHg); HTN II=Hypertension II (SBP$160); PP middle tertile=Pulse pressure 71–77 mmHg, and PP upper tertile=Pulse pressure
84–108 mmHg.
Model 1: age, race, education.
Model 2: age, race, education, history of high blood pressure, stroke, myocardial infarction, congestive heart failure, peripheral artery disease, diabetes mellitus, angina;
history of smoking, BMI, ever on hypertensive medication, glucose, cholesterol, and depression score.
Note: All Trails B models adjust for Trails A performance.
MMSE=Mini Mental State Exam; TMT, Part A=Trail Making Test, Part A; TMT, Part B=Trail Making Test, Part B; HVLT=Hopkins Verbal Learning Test (HVLT-I=immediate
recall; HVLT-D=delayed recall);
*p-value,0.05.
**p-value,0.01.
doi:10.1371/journal.pone.0027976.t004
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Ages 70–75 (n=248)
HTN I HTN II PP Middle Tertile PP Upper Tertile
HR (95% CI) HR (95% CI) HR (95% CI) HR (95% CI)
HVLT-D
Unadjusted 1.46 (0.74–2.87) 1.05 (0.49–2.27) 1.06 (0.54–2.07) 1.08 (0.55–2.11)
Model 1 1.40 (0.71–2.76) 0.91 (0.42–1.99) 1.15 (0.58–2.31) 1.25 (0.61–2.60)
Model 2 1.39 (0.68–2.84) 0.88 (0.39–2.02) 0.99 (0.47–2.09) 1.32 (0.63–2.78)
HVLT-I
Unadjusted 1.57 (0.78–3.13) 1.48 (0.70–3.14) 1.92 (0.96–3.87) 1.77 (0.87–3.58)
Model 1 1.52 (0.76–3.03) 1.28 (0.60–2.72) 2.58 (1.24–5.36)** 2.65 (1.21–5.80)*
Model 2 1.47 (0.71–3.02) 1.21 (0.55–2.66) 2.44 (1.11–5.39)* 3.13 (1.35–7.24)**
TMT, Part A
Unadjusted 2.52 (1.07–5.89)* 1.25 (0.45–3.46) 0.78 (0.35–1.73) 0.93 (0.43–1.99)
Model 1 2.38 (1.01–5.57)* 1.08 (0.39–3.00) 1.06 (0.47–2.39) 1.86 (0.81–4.26)
Model 2 2.13 (0.84–5.42) 1.02 (0.35–3.00) 1.01 (0.38–2.68) 1.46 (0.57–3.74)
TMT, Part B
Unadjusted 1.15 (0.61–2.16) 1.05 (0.53–2.07) 0.64 (0.31–1.34) 1.71 (0.95–3.07)
Model 1 1.09 (0.58–2.07) 0.87 (0.43–1.74) 0.68 (0.32–1.45) 1.83 (0.96–3.49)
Model 2 1.01 (0.51–1.99) 1.04 (0.50–2.16) 0.58 (0.25–1.32) 1.83 (0.91–3.71)
MMSE
Unadjusted 0.65 (0.25–1.70) 1.43 (0.60–3.41) 0.97 (0.40–2.33) 0.98 (0.41–2.37)
Model 1 0.56 (0.22–1.47) 1.02 (0.43–2.46) 1.02 (0.42–2.49) 1.00 (0.38–2.60)
Model 2 0.47 (0.17–1.30) 1.07 (0.41–2.80) 1.03 (0.39–2.72) 0.97 (0.34–2.73)
Ages 76–80 (n=88)
HTN I HTN II PP Middle Tertile PP Upper Tertile
HR (95% CI) HR (95% CI) HR (95% CI) HR (95% CI)
HVLT-D
Unadjusted 0.93 (0.39–2.25) 0.88 (0.39–2.00) 0.65 (0.27–1.55) 0.79 (0.34–1.83)
Model 1 0.85 (0.35–2.08) 0.92 (0.40–2.08) 0.64 (0.26–1.56) 0.79 (0.33–1.90)
Model 2 0.82 (0.27–2.47) 1.13 (0.38–3.43) 0.80 (0.27–2.31) 2.08 (0.54–7.98)
HVLT-I
Unadjusted 0.85 (0.38–1.91) 0.59 (0.27–1.30) 0.82 (0.37–1.81) 0.51 (0.21–1.20)
Model 1 0.81 (0.36–1.84) 0.61 (0.28–1.35) 0.80 (0.36–1.79) 0.47 (0.19–1.16)
Model 2 0.96 (0.38–2.45) 0.98 (0.37–2.59) 0.68 (0.27–1.71) 0.86 (0.25–2.93)
TMT, Part A
Unadjusted 0.68 (0.24–1.93) 1.15 (0.49–2.69) 0.77 (0.29–2.06) 1.03 (0.40–2.61)
Model 1 0.65 (0.23–1.85) 1.18 (0.50–2.76) 0.81 (0.29–2.24) 1.08 (0.40–2.94)
Model 2 0.80 (0.22–2.97) 2.56 (0.73–9.06) 0.52 (0.15–1.87) 2.01 (0.49–8.28)
TMT, Part B
Unadjusted 1.26 (0.52–3.03) 1.30 (0.59–2.88) 0.75 (0.31–1.79) 0.95 (0.41–2.18)
Model 1 1.20 (0.50–2.89) 1.39 (0.62–3.11) 0.74 (0.30–1.81) 1.05 (0.42–2.65)
Model 2 2.13 (0.65–6.95) 5.05 (1.42–18.04)* 1.24 (0.36–4.28) 5.12 (1.11–23.62)*
MMSE
Unadjusted -
# -
# 0.74 (0.23–2.44) 1.37 (0.47–4.02)
Model 1 -
# -
# 1.11 (0.30–4.09) 1.89 (0.58–6.19)
Model 2 -
# -
# 0.83 (0.20–3.47) 2.36 (0.40–13.83)
Reference group for HTN: Control group (SBP#139 mmHg): for PP: pulse pressure lower tertile (48–68 mmHg).
HTN Stage I=Hypertension Stage I (SBP 140–159 mmHg); HTN Stage II=Hypertension Satge II (SBP$160); PP middle tertile=Pulse pressure 71–77 mmHg, and PP
upper tertile=Pulse pressure 84–108 mmHg.
Model 1: age, race, education.
Model 2: age, race, education, history of high blood pressure, stroke, myocardial infarction, congestive heart failure, peripheral artery disease, diabetes mellitus, angina;
history of smoking, BMI, ever on hypertensive medication, glucose, cholesterol, and depression score.
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[95%CI=1.11; 23.62]) (Table 3 and 4). However, participants
aged between 70–75 years in both the middle and upper tertile
group had a greater risk of verbal learning impairment assessed by
HVLT-I (HR=2.44, 95% CI [1.11, 5.39]; HR=3.13)
[95%CI=1.35, 7.24], respectively (Table 4) when compared to
the control group.
Discussion
In this study we evaluated effects of elevated SBP or PP on
cognitive abilities, such as global cognitive function, speed of
processing, executive function, visuospatial function, and verbal
learning and memory, at baseline and over a 9-year period in non-
demented older community-dwelling female participants, in the
WHAS II. Our results showed that women aged between 76–80
years with SBP$160 mmHg or with PP$84 mmHg showed five
times higher incidence of impairment on TMT, Part B, a measure
of executive function, when compared to their control groups. We
also found that participants aged 70–75 years at baseline with
PP$84 mmHg had two- to three-fold higher incidence of
impairment in HVLT-I, a measure of verbal learning. Our data
suggest that elevated SBP and PP in older non-demented women
increases the risk for cognitive impairment in late-life.
With increasing life expectancy the number of older people,
especially older women who have a higher prevalence of HTN [3],
including elevated SBP and/or DBP, also increases. HTN in
midlife has been shown to be risk factor for lower cognitive
function in later life [7], but there is mixed evidence for an effect of
HTN in late-life on cognitive function, with information mostly
limited to measures of global cognitive function [14–18,37]. There
are few studies, with none looking specifically at older women,
reporting associations between elevated SBP and impairment in
specific cognitive abilities in late life [13,20,21], and findings from
these studies indicate that the affected cognitive abilities are
dependent on the participants’ age and the length of follow-up
[19–21]. Our results extend these findings to older women, aged
between 76–80 years, by showing detrimental effects of elevated
SBP$160 mmHg and PP$84 mmHg in late life on executive
function, in the absence of dementia, over a 9-year period. Our
study also suggests that PP is maybe a more sensitive measure for
cognitive decline, since it takes into account both the effects of SBP
and DBP.
Several mechanisms have been proposed and evaluated to
explain associations between elevated blood pressure and specific
cognitive abilities. It has been suggested that chronic HTN, by
hastening the atherosclerotic process in deep white matter vessels,
has a detrimental effect on sub-cortical white matter circuits [7],
which may account for impairment in specific cognitive abilities
such as executive function [38]. This seems to be confirmed by
imaging studies using magnetic resonance imaging (MRI) of
individuals with HTN which have found an increased number of
white matter abnormalities in the frontal lobe [39]. Our current
findings are in line with these studies, namely we found an
association between elevated SBP and impairment on TMT, Part
B, a measure of executive function.
There is a long standing hypothesis that HTN-associated
changes in the brain may interact with age-associated changes.
Thus the measured effect will be larger in older than in younger
hypertensive people [40] and this effect could be captured better
by measures of arterial stiffness such as PP rather than SBP. Our
study partially supports this hypothesis by showing the detrimental
effect of elevated SBP and also PP only in women aged 76–80, but
not those aged 70–75. However, verbal learning was found to be
worse in the younger group with the highest PP and this effect was
not seen in the older group and also not seen when evaluating the
effect of SBP. This could be partially explained by the different
brain areas involved in the different tasks, i.e. executive function
versus verbal learning, and their sensitivity to hypertension- and
age-associated changes.
There are some limitations of this study. First, the sample size
was relatively small and was composed of women, which may limit
generalization of these findings to the whole population. Second,
as is true in all observational studies, our results may be vulnerable
to confounding. It is possible that HTN and risk of cognitive
decline reflect the association of antihypertensive medication use
with yet another unmeasured variable. Third, we conducted
numerous comparisons, which could raise the possibility of our
significant findings being there by chance. Fourth, information on
mild cognitive impairment or dementia diagnosis is not currently
available, but adjudication is ongoing. Fifth, as in all studies with
aging cohorts, survival bias may be an issue, since people with
HTN might be more likely to die due to the increased mortality
risk associated with HTN. Last, there is selective loss to follow-up
of those most impaired, as found in most population-based studies,
but this would lead to underestimation of true rates of decline and
a more conservative estimate of our findings.
There are a number of advantages of this study. First, is its
population-based study which examined only female participants
initially free of cognitive and functional impairment and followed
them up to 9 years. Second, there were frequent and repeated
comprehensive cognitive assessments. Third, we were able to take
into consideration the effects of antihypertensive medications and
their effects on the brain and cognitive function by adjusting for
antihypertensive medication use.
Moderately elevated SBP levels have been considered accept-
able in older patients due to fear of hypoperfusion. However,
clinical trials, and most recently the Hypertension in the very
Elderly (HYVET) clinical trial [41], have shown that reducing
blood pressures in people older than 80 years from 173/91 to at
least 150/80 mmHg in 48% of the people in the active treatment
group resulted in decreased death from stroke and death from any-
cause. Although, it needs to be noted that the HYVET-Cog study
showed no benefits in terms of prevention of dementia or
incidence of global cognitive decline [42], which may have been
due to either the short follow-up secondary to the early
termination of the trial, or to the lack of treatment effect.
Although our study was an observational study, our results could
Note: All Trails B models adjust for Trails A performance.
MMSE=Mini Mental State Exam; TMT, Part A=Trail Making Test, Part A; TMT, Part B=Trail Making Test, Part B; HVLT=Hopkins Verbal Learning Test (HVLT-I=immediate
recall; HVLT-D=delayed recall);
*p-value,0.05.
**p-value,0.01.
doi:10.1371/journal.pone.0027976.t005
Table 5. Cont.
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SBP$160 mmHg in the older population, especially women,
could not only result in decreased mortality, but also in the
preservation of cognitive function, specifically executive function.
Our data suggests that elevated SBP or PP in older non-
demented women increases risk for late-life cognitive impairment.
These results warrant further, larger studies to evaluate possible
effects of elevated blood pressure in normal cognitive aging.
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